FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

771590007: Erenumab (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3706918013 Erenumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3706919017 Erenumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
55931000195112 erenumab it Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
854651000241110 erénumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
856701000241114 érénumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
71031000195110 Erenumab de Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Erenumab Is a Monoclonal antibody true Inferred relationship Some
Erenumab This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Calcitonin gene-related peptide receptor antagonist (disposition) true Inferred relationship Some
Erenumab Is a Substance with calcitonin gene-related peptide receptor antagonist mechanism of action (substance) true Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Erenumab-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Erenumab Inferred relationship Some 1
Erenumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Erenumab Inferred relationship Some 1
Product containing only erenumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Erenumab Inferred relationship Some 1
Erenumab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Erenumab Inferred relationship Some 1
Erenumab 70 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Erenumab Inferred relationship Some 1
Erenumab 70 mg/mL solution for injection This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Erenumab Inferred relationship Some 1
Product containing precisely erenumab 140 milligram/1 milliliter conventional release solution for injection (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Erenumab Inferred relationship Some 1
Product containing precisely erenumab 140 milligram/1 milliliter conventional release solution for injection (clinical drug) This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Erenumab Inferred relationship Some 1

This concept is not in any reference sets

Back to Start